Results 271 to 280 of about 1,672,248 (364)

Evidence of blood–brain barrier dysfunction and CSF immunoglobulin synthesis in Down Syndrome Regression Disorder

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Objectives This study sought to evaluate proteomic, metabolomic, and immune signatures in the cerebrospinal fluid of individuals with Down Syndrome Regression Disorder (DSRD). Methods A prospective case–control study comparing proteomic, metabolomic, and immune profiles in individuals with DSRD was performed.
Jonathan D. Santoro   +12 more
wiley   +1 more source

Tryptophan Metabolites in the Progression of Liver Diseases. [PDF]

open access: yesBiomolecules
Reshetova M   +10 more
europepmc   +1 more source

Liraglutide for idiopathic intracranial hypertension: a real‐world propensity score‐matched study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Objective Idiopathic intracranial hypertension (IIH) is a neurological disorder predominantly affecting young women with obesity, characterized by elevated intracranial pressure. While current treatments include weight loss counseling, medical therapies, and surgical interventions, their limitations necessitate exploring novel therapeutic ...
Ahmed Y. Azzam   +13 more
wiley   +1 more source

Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases. [PDF]

open access: yesFront Nutr
Perumal SK   +4 more
europepmc   +1 more source

Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Cases of myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) co‐occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ...
Young Nam Kwon   +24 more
wiley   +1 more source

Prospects of elafibranor in treating alcohol-associated liver diseases. [PDF]

open access: yesWorld J Gastroenterol
Cui WT, Xue HR, Wei DF, Feng XY, Wang K.
europepmc   +1 more source

Home - About - Disclaimer - Privacy